1. Home
  2. AHH vs RGNX Comparison

AHH vs RGNX Comparison

Compare AHH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AHH
  • RGNX
  • Stock Information
  • Founded
  • AHH 1979
  • RGNX 2008
  • Country
  • AHH United States
  • RGNX United States
  • Employees
  • AHH N/A
  • RGNX N/A
  • Industry
  • AHH Real Estate
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AHH Finance
  • RGNX Health Care
  • Exchange
  • AHH Nasdaq
  • RGNX Nasdaq
  • Market Cap
  • AHH 600.4M
  • RGNX 661.2M
  • IPO Year
  • AHH 2013
  • RGNX 2015
  • Fundamental
  • Price
  • AHH $6.80
  • RGNX $12.27
  • Analyst Decision
  • AHH Buy
  • RGNX Strong Buy
  • Analyst Count
  • AHH 4
  • RGNX 7
  • Target Price
  • AHH $8.38
  • RGNX $30.00
  • AVG Volume (30 Days)
  • AHH 627.3K
  • RGNX 669.4K
  • Earning Date
  • AHH 11-03-2025
  • RGNX 11-04-2025
  • Dividend Yield
  • AHH 12.08%
  • RGNX N/A
  • EPS Growth
  • AHH N/A
  • RGNX N/A
  • EPS
  • AHH 0.13
  • RGNX N/A
  • Revenue
  • AHH $544,168,000.00
  • RGNX $155,782,000.00
  • Revenue This Year
  • AHH N/A
  • RGNX $203.79
  • Revenue Next Year
  • AHH $2.61
  • RGNX $0.72
  • P/E Ratio
  • AHH $52.45
  • RGNX N/A
  • Revenue Growth
  • AHH N/A
  • RGNX 74.95
  • 52 Week Low
  • AHH $6.10
  • RGNX $5.04
  • 52 Week High
  • AHH $11.32
  • RGNX $13.39
  • Technical
  • Relative Strength Index (RSI)
  • AHH 45.82
  • RGNX 59.45
  • Support Level
  • AHH $6.55
  • RGNX $11.50
  • Resistance Level
  • AHH $6.81
  • RGNX $13.39
  • Average True Range (ATR)
  • AHH 0.13
  • RGNX 0.83
  • MACD
  • AHH 0.01
  • RGNX 0.11
  • Stochastic Oscillator
  • AHH 39.75
  • RGNX 64.44

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: